These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19888505)

  • 21. The association between serious infection and disease outcome in patients with rheumatoid arthritis.
    Iguchi-Hashimoto M; Hashimoto M; Fujii T; Hamaguchi M; Furu M; Ishikawa M; Ito H; Yamakawa N; Terao C; Yamamoto K; Yamamoto W; Ohmura K; Mimori T
    Clin Rheumatol; 2016 Jan; 35(1):213-8. PubMed ID: 26676809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months.
    Bae SC; Cho SK; Won S; Lee HS; Lee SH; Kang YM; Lee SH; Lee YA; Choe JY; Chung WT; Suh CH; Shim SC; Lee J; Yoon BY; Kim DW; Lee SS; Yoo WH; Kim JS; Jung YO; Nah SS; Lee CK; Song GG; Choi SJ; Joung CI; Koh H; Kim YJ
    Int J Rheum Dis; 2018 May; 21(5):1001-1009. PubMed ID: 29878615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort.
    Kotak S; Mardekian J; Horowicz-Mehler N; Shah A; Burgess A; Kim J; Gemmen E; Boyd H; Koenig A
    Value Health; 2015 Sep; 18(6):817-23. PubMed ID: 26409609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of therapy on functional ability of patients with rheumatoid arthritis].
    Kapidzić-Basić N; Selesković H; Mulić S
    Med Arh; 2007; 61(3):164-8. PubMed ID: 18232281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translation and validation of the Turkish language version of the Rheumatoid Arthritis Disease Activity Index-5.
    Sunar I; Yilmaz Tasdelen O; Garip Cimen Y; Bodur H
    Int J Rheum Dis; 2017 Dec; 20(12):2012-2019. PubMed ID: 24725498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
    Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
    Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Syngle A; Kaur S; Verma I; Syngle T; Syngle V
    Clin Rheumatol; 2017 Aug; 36(8):1715-1720. PubMed ID: 28634699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology.
    Carrara G; Bortoluzzi A; Sakellariou G; Silvagni E; Zanetti A; Govoni M; Scirè CA
    Clin Exp Rheumatol; 2019; 37(1):60-66. PubMed ID: 30148440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting.
    Vázquez I; Graell E; Gratacós J; Cañete JD; Viñas O; Ercilla MG; Gómez A; Hernández MV; Rodríguez-Cros JR; Larrosa M; Sanmartí R
    Clin Exp Rheumatol; 2007; 25(2):231-8. PubMed ID: 17543147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RADAI-5 to monitor rheumatoid arthritis.
    Leeb BF; Haindl PM; Brezinschek HP; Nothnagl T; Rintelen B
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-55-8. PubMed ID: 25365090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids?
    Kirwan J
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):182-3. PubMed ID: 16932680
    [No Abstract]   [Full Text] [Related]  

  • 33. Databases of patients with early rheumatoid arthritis in the USA.
    Sokka T; Willoughby J; Yazici Y; Pincus T
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S146-53. PubMed ID: 14969067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring functional disability in early rheumatoid arthritis: the validity, reliability and responsiveness of the Recent-Onset Arthritis Disability (ROAD) index.
    Salaffi F; Stancati A; Neri R; Grassi W; Bombardieri S
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S31-42. PubMed ID: 16273783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment and management of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.
    Stock T; Fleishaker D; Wang X; Mukherjee A; Mebus C
    Int J Rheum Dis; 2017 Aug; 20(8):960-970. PubMed ID: 28328159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.
    Rintelen B; Zwerina J; Herold M; Singer F; Hitzelhammer J; Halder W; Eichbauer-Sturm G; Puchner R; Stetter M; Leeb BF;
    BMC Musculoskelet Disord; 2016 Aug; 17(1):358. PubMed ID: 27550175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.